Mesenchymal stem cells reduce left ventricular mass in rats with doxorubicin-induced cardiomyopathy

Simple item page
dc.contributor.authorHaydardedeoglu, Ali Evren
dc.contributor.authorBoztok Özgermen, Deva Başak
dc.contributor.authorYavuz, Orhan
dc.date.accessioned13.07.201910:50:10
dc.date.accessioned2019-07-16T09:15:18Z
dc.date.available13.07.201910:50:10
dc.date.available2019-07-16T09:15:18Z
dc.date.issued2018
dc.departmentVeteriner Fakültesi
dc.description.abstractDoxorubicin is a drug that used by a majority in the treatment of carcinomas. The most obvious known side effect is cardiomyopathy. Many studies have been carried out to eliminate side effects of the doxorubicin, and stem cell studies have been added in recent years. In this study, it was aimed to investigate fetal-derived mesenchymal stem cells (F-MSCs) treatment of doxorubicin-induced cardiomyopathy by morphological methods. A total of 24 rats which were divided into three separate groups (Control, sham, treatment), each consisting of 8 male rats were used. In sham and treatment group, Adriamycin was administered in a single dose by tail injection to perform cardiotoxicity. In the treatment group, F-MSCs were intra-peritoneally administrated. Then, rats were euthanized and their hearts were photographed at the level of papillary muscle. and thickness, diameters and surface area levels were measured. Left ventricular mass (LVM) and left ventricular mass index (LVMI) were calculated after measurement. The sham group, LVM and LVMI levels were found to significantly lower (p<0.05) than control and treatment group. In the one hand, LVMI levels of rats in treatment group was statistically similar (p>0.05) to control group. Similarly, LVM levels of control and treatment groups were close to each other while this level of sham group was lower. It has been shown that F-MSC administrations in rats with doxorubicin-induced cardiomyopathy have adverse effect on LVM and LVMI values. In addition, the intra-peritoneal MSC administrations may be an alternative to other injection routes such as intra-venous and intra-cardiac administrations.
dc.identifier.doi10.4067/S0717-95022018000100048
dc.identifier.endpage53en_US
dc.identifier.issn0717-9502
dc.identifier.issn0717-9367
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage48en_US
dc.identifier.urihttps://doi.org/10.4067/S0717-95022018000100048
dc.identifier.urihttps://hdl.handle.net/20.500.12451/4346
dc.identifier.volume36en_US
dc.identifier.wosWOS:000438813400008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSociedad Chilena de Anatomía
dc.relation.ispartofInternational Journal of Morphology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdriamycin
dc.subjectHeart
dc.subjectMorphometry
dc.subjectPluripotent Stem Cell
dc.titleMesenchymal stem cells reduce left ventricular mass in rats with doxorubicin-induced cardiomyopathy
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
haydardedeoglu-ali evren-2018.pdf
Size:
407.88 KB
Format:
Adobe Portable Document Format
Description:
Tam Metin / Full Text
Download

Collections

Makale Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu